Stock-Based Compensation

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

The Compensation Committee of our Board of Directors granted 385,688 stock options and 489,892 restricted stock units ("RSUs"), and our electing non-employee directors received 57,021 deferred share units ("DSUs") during the six months ended June 30, 2022 under our Omnibus Equity Incentive Plan. The weighted average exercise price per share and weighted average fair value per share of the stock options granted in the six months ended June 30, 2022 was $10.08 and $5.55, respectively. We estimated the fair value of the stock options using the following assumptions in our Black-Scholes model:

Dividend yield

0.40%

Expected volatility

58.28%

Risk-free interest rate

1.93%

Expected term (in years)

6.5 years

We measure the fair value of grants of RSUs and DSUs based on the closing market price of a share of our common stock on the date of the grant. The weighted average fair value per share was $10.08 for RSUs and $8.25 for DSUs granted during the six months ended June 30, 2022.

In the three months ended June 30, 2022 and 2021, we recognized $0.6 million and $15.3 million, respectively, of stock-based compensation expense. The majority of the expense, $0.6 million and $13.4 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of sales.

In the six months ended June 30, 2022 and 2021, we recognized $1.0 million and $16.0 million, respectively, of stock-based compensation expense. The majority of the expense, $1.0 million and $14.1 million, respectively, was recorded in selling and administrative expense in the Condensed Consolidated Statements of Operations, with the remaining expense recorded in cost of sales.

In the three and six months ended June 30, 2021, the expense includes $14.7 million due to the Change in Control accelerated vesting provisions of certain of our awards. For the purpose of these grants, a Change in Control occurred when Brookfield and any affiliates thereof ceased to own stock of the Company that constitutes at least thirty percent (30%) or thirty-five percent (35%), as applicable, of the total fair market value or total voting power of the stock of the Company (the "Change in Control"). Out of the $14.7 million recorded with the Change in Control, $0.9 million accelerated at the 35% ownership level and the remaining $13.8 million accelerated at the 30% ownership level.

As of June 30, 2022, the unrecognized compensation cost related to the unvested portion of all stock-based awards was approximately $6.4 million and is expected to be recognized over the remaining vesting period of the respective grants.